Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640245 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
A Phase 2 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT05640245: Completed Phase 2 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
NCT05640245 is a Phase 2 study of Arthritis, Psoriatic that has completed, run by MoonLake Immunotherapeutics. The registered enrollment target is 207 participants, below the 563-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05640245, a Phase 2 study of Arthritis, Psoriatic, has completed, sponsored by MoonLake Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
Primary Outcome
Proportion of participants who achieve ACR50 compared with baseline
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Sonelokimab
Study Locations (20)
Other
- Clinical Site - Pleven
- Clinical Site - Pleven
- Clinical Site - Plovdiv
- Clinical Site - Plovdiv
- Clinical Site - Rousse
- Clinical Site - Sofia
- Clinical Site - Stara Zagora
- Clinical Site - Varna
- Clinical Site - Ostrava
- Clinical Site - Tallinn
- Clinical Site - Tartu
- Clinical Site - Hamburg
- Clinical Site - Herne
- Clinical Site - Budapest
- Clinical Site - Budapest
- Clinical Site - Budapest
- Clinical Site - Szentes
- Clinical Site - Székesfehérvár
California
- Clinical Site - Rancho Mirage
Pennsylvania
- Clinical Site - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 2 |
What the finished NCT05640245 record still lists
NCT05640245 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 563-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05640245 names 20 study sites across 3 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05640245 about?
NCT05640245 is a clinical study titled "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
What is the current status of trial NCT05640245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2022-12-13. Estimated completion is 2024-01-15.
What conditions does trial NCT05640245 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT05640245?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Sonelokimab (DRUG).
Who is sponsoring clinical trial NCT05640245?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640245 being conducted?
This trial has 20 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05640245's enrollment target sits among peer trials
207 12th of 16 higher than 5 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
RECRUITING · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI